Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

What is ALXN's EBITDA?

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

EBITDA is 
$3.1B (1Y +7.37% )

ALXN Stock Price & EBITDA

Note: Stonk = Stock. Both words are used interchangeably. 🙂

Historical (All-Time) Stats for EBITDA

chevron_right 2021 $722.1M +655x *
( +27.2% / year avg)
chevron_left 1995 -$1.1M
vertical_align_top Peak $3.1B +26.3x *
vertical_align_bottom Bottom -$122.6M
arrow_drop_up # Up Years 19 19 of 27
years up.
arrow_drop_down # Down Years 8
Up Years = Positive (0%+) YoY change
Down Years = Zero or Negative (0% or less) YoY change

Key Points (Stonk Price Comparison)

  • ALXN's stock price has rallied +4,601% from $2.31 in 1995 , or -0.07x the rate relative to it's ebitda over the same period.
  • If ALXN grows it's stock at the same rate as it's ebitda (+27.2%/year) , it's stock price will grow +1,108% and hit $1205.54 over the next 10 years.
  • ALXN's stock price has gone up 0 of the 19 years (0%) it's ebitda were also up.
* A modified method (see: here) is used to calculate changes that involve negative numbers.
  • ALXN Historical EBITDA Table
    in $ million
    * A modified method (see: here) is used to calculate changes that involve negative numbers.
    Year EBITDA YoY % Change* Stock Price YoY % Change (Stock Price)
    4/1/2021 $722 -76.7% - -
    4/1/2020 $3,103 28.9% - -
    4/1/2019 $2,406 34.9% - -
    4/1/2018 $1,783 36.1% - -
    4/1/2017 $1,310 69.4% - -
    4/1/2016 $773 -12.1% - -
    4/1/2015 $880 -0.6% - -
    4/1/2014 $885 50.5% - -
    4/1/2013 $588 51.3% - -
    4/1/2012 $388 69.8% - -
    4/1/2011 $228 59.2% - -
    4/1/2010 $143 56.3% - -
    4/1/2009 $91 693.4% - -
    4/1/2008 $11 -109.4% - -
    4/1/2007 $-122 5.9% - -
    4/1/2006 $-115 -4.0% - -
    4/1/2005 $-120 72.8% - -
    4/1/2004 $-69 -9.9% - -
    4/1/2003 $-77 10.5% - -
    4/1/2002 $-70 119.9% - -
    4/1/2001 $-31 29.8% - -
    4/1/2000 $-24 203.2% - -
    4/1/1999 $-8 -44.9% - -
    4/1/1998 $-14 226.7% - -
    4/1/1997 $-4 -19.6% - -
    4/1/1996 $-5 409.1% - -
    4/1/1995 $-1 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • ebitda (also known as Earnings before Interest, Taxes, Depreciation, and Amortization) is a measure of a company's overall financial performance and is used as an alternative to net income in some circumstances. ebitda, however, can be misleading because it strips out the cost of capital investments like property, plant, and equipment.

    For more detailed definitions, please see Investopedia.